Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHOENIX: Phase III trial of tinlarebant in geographic atrophy secondary to age-related macular degeneration
CTR20241357Phase 3Active
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tinlarebant in age-related macular degeneration (AMD), sponsored by BrightGene Bio-Medical Technology. Started Oct 2024; status: active.
02
Drugs
tinlarebant
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on CTR20241357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241357.